This week, Flagship held the Firm’s Annual Meeting in Boston. Each year at this meeting we recognize an executive from a portfolio company who demonstrates great passion for and commitment to pioneering advancements in the life sciences. The recipient of this year’s award is David Schenkein, M.D., chief executive officer of Agios Pharmaceuticals (NASDAQ: AGIO).
At Agios, Dr. Schenkein has assembled a deep bench of scientific and business leaders who are bringing into reality Agios’ mission to discover and develop first-in-class therapies to treat cancer and rare genetic metabolic disorders. The Company has a highly active R&D engine across several therapeutic areas, as well as multiple investigational medicines in clinical and preclinical development to address unmet needs for patients with cancer and rare genetic disorders.
Doug Cole, managing partner at Flagship, shared thoughts on Dr. Schenkein and the award:
“David sets the standard for life sciences leaders with his commitment to patients and passion for translating cutting-edge science into life-changing products. His integrity and vision represent the spirit of biotechnology innovation at its best. We congratulate David on his leadership in creating a company that we at Flagship are very proud of.”
To read more about the award and Dr. Schenkein, please read this press release: http://prn.to/2fi1elH